The urinary excretion of cystine, as determined on the polarograph, varies, in normal adults, between 40 and 80 mg. daily (1) . It may be increased either as a result of a low renal threshold for cystine or a raised plasma cystine concentration. Cystinuria due to a low renal threshold occurs in 'classical cystinuria,' the Fanconi syndrome and hepatolenticular degeneration (2) . In such conditions the excretion of cystine is usually large, 0.5 to 1.0 g. daily, and is associated with other characteristic changes in the pattern of amino acids excreted. A moderately increased excretion of cystine has been described in patients with liver disease (3) (4) (5) and this has been shown, by paper chromatography, to result from a raised plasma cystine concentration. It has been suggested that the increased urinary cystine in these patients might form a sensitive index of impaired amino acid metabolism (6) .
Using the quantitatively more accurate method of polarography for cystine assay we have reinvestigated the plasma level and urinary output of cystine in cases of liver disease. In addition we have carried out cystine and cysteine tolerance tests comparing the results found in patients with chronic liver injury with those found in normal subjects. METHODS Polarography (7) was used to measure the concentration of cystine in plasma and the output of cystine in urine. Technical details have already been published (8) .
This method does not distinguish between cystine and cysteine as the S-S linkage is reduced to the S-H form in the polarizing cell. It is improbable that cysteine, following its ingestion, would remain for long in the reduced state in the plasma as the oxygen present, at normal plasma pH, would rapidly cause its conversion to cystine. This problem has been discussed in more detail elsewhere (8) 2) The excretion of 'cystine' in the urine In 13 adult normal males the output of 'cystine' varied between 43 and 70 mg. per 24 hours, with a mean of 61 mg. In 12 adult normal females the range was between 28 and 53 mg. of 'cystine' with a mean of 44 mg. per 24 hours. In patients with cirrhosis the 24-hour excretion of 'cystine' was measured on 90 separate occasions in 19 different patients (10 male, 9 female), the majority being represented by more than one urine specimen. As the output of 'cystine' was not constant for any given patient but fluctuated with the severity of the illness (Figure 2 ) each estimation is treated as a separate entity on the histogram (Figure 3 The results are given in Table II and Figure 4 ; the control observations were obtained from seven similar studies on normal subjects and are published in detail elsewhere (8) . In five of the six patients the cystine tolerance curve deviated little from that found in the controls although the peak was somewhat delayed. In the case of D.A. the fasting plasma 'cystine' level was elevated and the initial rise in response to the loading dose of cystine was exaggerated and was maintained throughout the six-hour experimental period. This man had advanced cirrhosis following an attack of serum hepatitis. Clinically he was the most seriously ill patient in this group. 4 ) Effect of feeding 1-cysteine HCI, 3.0 g., to patients uith hepatic cirrhosis It was intended to give 6.0 g. of 1-cysteine HCl containing approximately an equimolecular amount of sulphur to 5.0 g. of cystine. Eventually, for reasons stated earlier, it was decided to give a smaller dose of cysteine to the patients with cirrhosis. As a pilot experiment 2.0 g. of 1-cysteine HCl was given; this produced no toxic symptoms but did result in a sharp rise in the plasma 'cystine' concentration. The dose given in subsequent tests, and also to the control subjects, was 3.0 g. The average figure for the four normal subjects shows that the plasma 'cystine' rose from a fasting level of 9.0 ug. per ml. to 15.3 ug. per ml. at one hour but returned to the fasting level by the end of two hours. In the patients with cirrhosis the rise was very much greater. In the case of M. C. the peak 'cystine' concentration, reached at one hour, was 60 ug. per ml. and it exceeded 30 ,ug. per ml. in all of the cases investigated. The results are given in detail in Table III and also in Figure 5 .
Of the five patients with cirrhosis fed cysteine two (G. M. and A. R.) had lieno-renal anastomoses which had been constructed for the relief of portal hypertension. The results in these two cases did not differ materially from those found in the three patients with cirrhosis but no clinical evidence of portal hypertension. The presence of these large portal-systemic anastomotic veins did not lead to an increased abnormality in the shape of the cysteine tolerance curves.
5) 'Cystine' clearance in patients weith liver injury
In normal subjects the urine excretion of 'cystine' varies directly with the plasma concentration (8) . In certain of the cystine and cysteine tolerance tests carried out on patients with cirrhosis urine samples were collected during the experimental period and it was found that the 'cystine' clearance was the same in these patients as in the controls, that is around 2 to 4 ml. per min. at all plasma concentrations investigated. These results have been expressed graphically (Figure 6 ), plasma' cystine' concentration being plotted against the minute excretion of 'cystine.' The figures show a highly significant correlation between the plasma level and the urine excretion of 'cystine,' the correlation coefficient is r = 0.8020. very great increase in the minute excretion of 'cystine'; this is particularly obvious when the results are compared with those found in D. A., the only patient who showed a marked rise in the plasma 'cystine' level after the ingestion of cystine (see Table IV ). It was stated earlier that cysteine is unlikely to exist as such in the blood but it remains possible that the severe liver damage in C. G. resulted in a slower oxidation of the fed cysteine. If, as is also possible, cysteine is reabsorbed more readily than cystine by the renal tubule this would account for the lower minute excretion of 'cystine' by C. G. at the very high blood levels achieved and also for the rising urine excretion co-incident with the falling blood level during the latter part of the test period.
DISCUSSION
In patients with hepatic cirrhosis the fasting plasma 'cystine' level is frequently increased as is the 24-hour excretion of 'cystine.' In the normal individual the amount of 'cystine' excreted in the urine depends directly on the plasma concentration (8) and our results indicate that this also holds for patients with liver injury. The increase in the urinary 'cystine' in patients with acute hepatitis and cirrhosis therefore simply reflects the raised concentration of 'cystine' in the plasma. In general the higher plasma levels of 'cystine' occurred in those patients with the most marked evidence of severe parenchymal liver damage. The quantities of 'cystine' excreted by the more severely ill patients were of the same order that Harris and Warren (14) found in heterozygous cystinuric subjects. However the urine of patients with liver disease did not show the characteristic 'cystine, lysine pattern' of amino acid excretion of classical cystinuria but did show other abnormalities of amino acid excretion which have been described elsewhere (6) .
In only one of the six patients with hepatic cirrhosis and impaired tests of liver function (D. A.) did the cystine tolerance curve differ significantly from normal. The explanation may be that cystine, which is very insoluble, is slowly absorbed from the gut and does not reach the liver in high concentration. It cannot act, therefore, as a significant load and a markedly abnormal tolerance curve is not produced except in the presence of very severe liver damage. Intravenous administration of cystine would be necessary to clarify this point but because of its extreme insolubility at body pH this is impracticable.
Cysteine, being very soluble, is rapidly absorbed and presumably reaches the liver in relatively high concentration either as cysteine or as cystine. Consequently 3.0 g. of 1-cysteine HCI produced a greater percentage rise in the plasma 'cystine' level of normal subjects than did 5.0 g. of cystine. Other workers have reported results similar to these, on normal subjects, and have offered the same explanation (8, 12, 15) . These authors pointed out that this was also the probable explanation of the results of the feeding experiments of Brand, Cahill, and Harris (16) who, however, analyzed only urine for cystine and interpreted their results differently. The patients with cirrhosis fed 3.0 g. of 1-cysteine HQ all showed a rise in the plasma level markedly greater than that produced by the same dose in the control subjects. This phenomenon could be due either to a reduced ability on the part of the liver to metabolize cystine (or possibly only cysteine) or to 308 the portal blood by-passing the liver via collateral venous channels, which can often be demonstrated in such patients. The available evidence supports the former theory. Large portal-systemic anastomotic veins in C. G. or I. M. were not detected at the time of the test and none were found at a subsequent post mortem examination on M. C. In the two patients with lieno-renal shunts (G. M. and A. R.) the peak 'cystine' levels in the cysteine tolerance curves were lower than in the other three patients. It is more likely, therefore, that the high levels of plasma 'cystine' found indicate a reduced ability on the part of the liver to metabolize cystine (or possibly only cysteine) at the normal rate, probably due to damage to one or more of the enzyme systems specifically handling cystine in the liver.
In these experiments only 'cystine' metabolism has been studied quantitatively both in the fasting state and after the stress of an oral load and no conclusions can be drawn therefore, from this work, about the metabolism of other amino acids. The possibility remains that in the course of progressive hepatic disease, as different enzyme systems are affected, so the ability of the liver to utilize individual amino acids becomes impaired. Chromatographic studies reported elsewhere also support this theory (6) . Cystine however appears to be one of the first amino acids to show disturbed metabolism in liver disease. SUMMARY 1. The plasma 'cystine' concentration and urinary 'cystine' excretion have been measured in patients with acute and chronic liver disease, using a polarographic method of determination.
2. Comparison with the normal shows that: 1) The average figure for the plasma 'cystine' level is higher for patients with hepatic cirrhosis and shows a wide range of variation.
2) The average output of 'cystine' in the urine per 24 hours is greater in the patients with liver disease.
3) The increased output of 'cystine' is directly due to the raised plasma concentration and not to any alteration in the renal clearance. The higher figures for both plasma and urine are found in those patients with the more severe liver injury.
3. Tolerance tests have been carried out in which cystine or cysteine were fed to patients with chronic liver injury and the results compared with similar tests on normal subjects. Only in very severe liver damage does the ingestion of cystine produce an abnormal rise in the plasma 'cystine' level. On the other hand cysteine caused markedly abnormal tolerance curves in all the patients so investigated. 4 . The abnormal plasma 'cystine' levels following the ingestion of cysteine appear to be due to liver damage and not to portal blood by-passing the liver via collateral venous channels.
